Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 24 studies | 39% ± 16% | |
pericyte | 22 studies | 40% ± 20% | |
fibroblast | 17 studies | 40% ± 18% | |
smooth muscle cell | 15 studies | 34% ± 12% | |
microglial cell | 9 studies | 27% ± 10% | |
type I pneumocyte | 8 studies | 41% ± 17% | |
endothelial cell of artery | 7 studies | 31% ± 20% | |
macrophage | 7 studies | 27% ± 11% | |
interneuron | 6 studies | 30% ± 13% | |
endothelial cell of lymphatic vessel | 6 studies | 34% ± 16% | |
GABAergic neuron | 6 studies | 35% ± 18% | |
vein endothelial cell | 5 studies | 35% ± 24% | |
B cell | 4 studies | 24% ± 5% | |
cardiac muscle cell | 4 studies | 23% ± 10% | |
myofibroblast cell | 4 studies | 22% ± 7% | |
glutamatergic neuron | 4 studies | 44% ± 15% | |
brush cell | 4 studies | 55% ± 23% | |
capillary endothelial cell | 4 studies | 33% ± 16% | |
hepatic stellate cell | 3 studies | 57% ± 17% | |
neuron | 3 studies | 31% ± 3% | |
oligodendrocyte precursor cell | 3 studies | 19% ± 2% | |
CD4-positive, alpha-beta T cell | 3 studies | 22% ± 3% | |
CD8-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
endocardial cell | 3 studies | 35% ± 15% | |
endothelial cell of vascular tree | 3 studies | 41% ± 19% | |
muscle cell | 3 studies | 23% ± 5% | |
adventitial cell | 3 studies | 23% ± 8% | |
T cell | 3 studies | 23% ± 5% | |
monocyte | 3 studies | 17% ± 1% | |
natural killer cell | 3 studies | 23% ± 3% | |
lymphocyte | 3 studies | 31% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 2737.52 | 359 / 359 | 99% | 12.41 | 284 / 286 |
thymus | 100% | 2741.53 | 652 / 653 | 99% | 12.89 | 600 / 605 |
intestine | 100% | 3161.17 | 965 / 966 | 98% | 10.98 | 519 / 527 |
lung | 100% | 8405.22 | 578 / 578 | 98% | 10.16 | 1130 / 1155 |
breast | 100% | 3251.78 | 459 / 459 | 97% | 7.26 | 1089 / 1118 |
adrenal gland | 99% | 2147.93 | 256 / 258 | 95% | 19.93 | 218 / 230 |
esophagus | 96% | 2951.55 | 1393 / 1445 | 97% | 11.61 | 177 / 183 |
bladder | 100% | 2516.33 | 21 / 21 | 90% | 7.48 | 456 / 504 |
prostate | 97% | 1949.79 | 237 / 245 | 91% | 4.87 | 459 / 502 |
uterus | 98% | 2680.58 | 167 / 170 | 88% | 6.67 | 406 / 459 |
skin | 88% | 1270.67 | 1594 / 1809 | 98% | 10.25 | 464 / 472 |
brain | 82% | 989.51 | 2164 / 2642 | 99% | 7.97 | 700 / 705 |
kidney | 82% | 1078.87 | 73 / 89 | 81% | 9.49 | 727 / 901 |
liver | 68% | 732.35 | 153 / 226 | 92% | 5.56 | 372 / 406 |
ovary | 100% | 4278.37 | 180 / 180 | 37% | 1.36 | 161 / 430 |
pancreas | 9% | 72.46 | 28 / 328 | 98% | 13.90 | 175 / 178 |
adipose | 100% | 4537.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7128.03 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 13.29 | 29 / 29 |
spleen | 100% | 4807.33 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.36 | 1 / 1 |
heart | 100% | 3758.94 | 860 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 7.20 | 43 / 45 |
eye | 0% | 0 | 0 / 0 | 80% | 3.60 | 64 / 80 |
muscle | 75% | 754.95 | 601 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 69% | 1238.84 | 644 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0009966 | Biological process | regulation of signal transduction |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_0007217 | Biological process | tachykinin receptor signaling pathway |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0008277 | Biological process | regulation of G protein-coupled receptor signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0006915 | Biological process | apoptotic process |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0006468 | Biological process | protein phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0045444 | Biological process | fat cell differentiation |
GO_0005886 | Cellular component | plasma membrane |
GO_0016607 | Cellular component | nuclear speck |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0031965 | Cellular component | nuclear membrane |
GO_0005080 | Molecular function | protein kinase C binding |
GO_0005543 | Molecular function | phospholipid binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0004672 | Molecular function | protein kinase activity |
GO_0004703 | Molecular function | G protein-coupled receptor kinase activity |
GO_0047696 | Molecular function | beta-adrenergic receptor kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GRK5 |
Protein name | GRK5 protein G protein-coupled receptor kinase 5 (EC 2.7.11.16) (G protein-coupled receptor kinase GRK5) |
Synonyms | GPRK5 |
Description | FUNCTION: Serine/threonine kinase that phosphorylates preferentially the activated forms of a variety of G-protein-coupled receptors (GPCRs). Such receptor phosphorylation initiates beta-arrestin-mediated receptor desensitization, internalization, and signaling events leading to their down-regulation. Phosphorylates a variety of GPCRs, including adrenergic receptors, muscarinic acetylcholine receptors (more specifically Gi-coupled M2/M4 subtypes), dopamine receptors and opioid receptors. In addition to GPCRs, also phosphorylates various substrates: Hsc70-interacting protein/ST13, TP53/p53, HDAC5, and arrestin-1/ARRB1. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors. Phosphorylation of HDAC5, a repressor of myocyte enhancer factor 2 (MEF2) leading to nuclear export of HDAC5 and allowing MEF2-mediated transcription. Phosphorylation of TP53/p53, a crucial tumor suppressor, inhibits TP53/p53-mediated apoptosis. Phosphorylation of ST13 regulates internalization of the chemokine receptor. Phosphorylates rhodopsin (RHO) (in vitro) and a non G-protein-coupled receptor, LRP6 during Wnt signaling (in vitro). . |
Accessions | ENST00000392870.3 P34947 Q24JT8 |